Noninvasive Molecular Imaging of the Enhanced Permeability and Retention Effect by 64Cu-Liposomes: In vivo Correlations with 68Ga-RGD, Fluid Pressure, Diffusivity and 18F-FDG
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background: The accumulation of liposome encapsulated chemotherapy in solid cancers is dependent on the presence of the enhanced permeability and retention (EPR) effect. Positron emission tomography (PET) imaging with a liposome encapsulated radioisotope, such as liposome encapsulated Cu-64 ( 64 Cu-liposome) may help to identify tumors with high liposome accumulation, and thereby stratify patients based on expected benefit from liposomal chemotherapy. However, intravenous administration of liposomes without a cytotoxic content is complicated by the accelerated blood clearance (ABC) phenomenon for succeeding therapeutic liposome dosing. Alternative markers for assessing the tumor’s EPR level are therefore warranted. Materials and Methods: To increase our understanding of EPR variations and to ultimately identify an alternative marker for the EPR effect, we investigated the correlation between 64 Cu-liposome PET/CT (EPR effect) and 68 Ga-RGD PET/CT (neoangiogenesis), 18 F-FDG PET/CT (glycolysis), diffusion-weighted MRI (diffusivity) and interstitial fluid pressure in two experimental cancer models (CT26 and COLO 205). Results: 64 Cu-liposome and 68 Ga-RGD SUV max displayed a significant moderate correlation, however, none of the other parameters evaluated displayed significant correlations. These results indicate that differences in neoangiogenesis may explain some EPR variability, however, as correlations were only moderate and not observed for SUV mean , 68 Ga-RGD is probably insufficient to serve as a stand-alone surrogate marker for quantifying the EPR effect and stratifying patients. Keywords: EPR effect, liposome, positron emission tomography, neoangiogenesis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Molecular imaging modalities have the potential for detecting EPR effects to formulate better therapeutic NPs and select patients with a high EPR effect [122].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Molecular imaging of cancer with positron emission tomography
Gambhir, S. S. (2002) · Nature Reviews Cancer · doi:10.1038/nrc882 · Cited by 1,656
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Research works printed but not linked: 7
- Harrington, 2001, Clin Cancer Res, 7, 243
- Eliceiri, 2000, Cancer J, 6, S245
- Yuan, 1995, Cancer Res, 55, 3752
- Boucher, 1990, Cancer Res, 50, 4478, 10.16373/j.cnki.ahr.150049 · doi:10.16373/j.cnki.ahr.150049
- Jain, 1987, Cancer Res, 47, 3039
- Yuan, 1994, Cancer Res, 54, 3352
- Wong, 2013, Am J Nucl Med Mol Imaging, 3, 32
Cited by
Recent advances and clinical translation of liposomal delivery systems in cancer therapy
Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106688 · Cited by 215
Liposomes: Biomedical Applications
Kim, E., & Jeong, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.1.27 · Cited by 143
Giordani, S., Marassi, V., Zattoni, A., Roda, B., & Reschiglian, P. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115751 · Cited by 141
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
“Molecular imaging modalities have the potential for detecting EPR effects to formulate better therapeutic NPs and select patients with a high EPR effect [122].”
BackgroundBruno, F., Granata, V., Bellisari, F. C., Sgalambro, F., Tommasino, E., Palumbo, P., Arrigoni, F., Cozzi, D., Grassi, F., Brunese, M. C., et al. (2022) · Cancers · doi:10.3390/cancers14071626 · Cited by 76
Metadata
- Authors
- Børresen, B., Hansen, A. E., Fliedner, F. P., Henriksen, J. R., Elema, D. R., Brandt-Larsen, M., Kristensen, L. K., Kristensen, A. T., Andresen, T. L., & Kjær, A.
- Affiliations
- University of Copenhagen (DK)
- Technical University of Denmark (DK)
- Copenhagen University Hospital (DK)
- Corresponding author
- Kjær, Andreas
- ORCID
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2020-11
- Volume
- Volume 15
- Pages
- 8571-8581
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- PMC
- PMC7646401
- OpenAlex
- W3096535406
- Semantic Scholar
- d20fe9e842b23f54fbd63cde41a9aaf97e4f22ac
- Cited by
- 28
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 4 · 2021: 3
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Nanomedicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
- Funders
- Lundbeckfonden (R302-2018-2266)
- Novo Nordisk Fonden (NNF15OC0016796)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- enhanced permeability and retention effect, liposomal chemotherapy, tumor neoangiogenesis, 18F-FDG, tumor glycolysis, diffusion-weighted imaging, interstitial fluid pressure, accelerated blood clearance, PET/CT imaging, CT26 cells, surrogate markers
- MeSH terms
- Positron Emission Tomography Computed Tomography, Animals, Contrast Media, Copper Radioisotopes, Diffusion, Female, Gallium Radioisotopes, Humans, Liposomes, Magnetic Resonance Imaging, Mice, Inbred BALB C, Neoplasms, Neovascularization, Pathologic, Oligopeptides, Permeability, Pressure, Colorectal Neoplasms, Radiopharmaceuticals, Fluorodeoxyglucose F18, Xenograft Model Antitumor Assays, Cell Line, Tumor, Molecular Imaging, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.